Cargando…

Healthcare resource utilization and costs among children with cystic fibrosis in the United States

BACKGROUND: Adverse health impacts of cystic fibrosis (CF) can be present in children before respiratory complications are observed. Children with CF show progressive health decline, with increasing lung function decline in adolescence. This study aims to quantify the healthcare resource utilization...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thorat, Teja, McGarry, Lisa J., Bonafede, Machaon M., Limone, Brendan L., Rubin, Jaime L., Jariwala‐Parikh, Krutika, Konstan, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456795/ https://www.ncbi.nlm.nih.gov/pubmed/34138523 http://dx.doi.org/10.1002/ppul.25535

Ejemplares similares

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

The burden of cystic fibrosis in the Medicaid population
por: Hassan, Mariam, et al.
Publicado: (2018)

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
por: Duckers, Jamie, et al.
Publicado: (2021)

Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
por: Bonafede, Machaon M., et al.
Publicado: (2019)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
por: Bonafede, Machaon M, et al.
Publicado: (2013)

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke
por: Johnson, Barbara H, et al.
Publicado: (2016)

Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations
por: Accortt, Neil A, et al.
Publicado: (2017)

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data
por: McGarry, Lisa J., et al.
Publicado: (2023)

Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
por: Bonafede, Machaon, et al.
Publicado: (2021)

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls
por: Bedenbaugh, Angela V, et al.
Publicado: (2021)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure
por: Bonafede, Machaon, et al.
Publicado: (2018)

The Cystic Fibrosis Impact Questionnaire: qualitative development and cognitive evaluation of a new patient-reported outcome instrument to assess the life impacts of cystic fibrosis
por: McCarrier, Kelly P., et al.
Publicado: (2020)

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
por: Hubert, Dominique, et al.
Publicado: (2021)

Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
por: Hubert, Dominique, et al.
Publicado: (2021)

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
por: VanDevanter, Donald R, et al.
Publicado: (2010)

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
por: VanDevanter, Donald R., et al.
Publicado: (2021)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Managing Cystic Fibrosis in Polish Healthcare
por: Rachel, Marta, et al.
Publicado: (2020)

Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities
por: Lanzkron, Sophie, et al.
Publicado: (2019)

Physical activity for cystic fibrosis: perceptions of people with cystic fibrosis, parents and healthcare professionals
por: Denford, Sarah, et al.
Publicado: (2020)

Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims data
por: Beyrer, Julie, et al.
Publicado: (2021)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns
por: Desai, Sameer, et al.
Publicado: (2023)

Utilization of the Healthy Eating Index in Cystic Fibrosis
por: Bass, Rosara Milstein, et al.
Publicado: (2022)

Data Resource Profile: The UK Cystic Fibrosis Registry
por: Taylor-Robinson, David, et al.
Publicado: (2018)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
por: Thorat, Teja, et al.
Publicado: (2018)

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
por: Johnson, Barbara H., et al.
Publicado: (2015)

Health Human Resources Guidelines: Minimum Staffing Standards and Role Descriptions for Canadian Cystic Fibrosis Healthcare Teams
por: McIntosh, Ian D.
Publicado: (2016)

Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
por: Lassenius, Mariann I., et al.
Publicado: (2019)

Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population
por: Bonafede, Machaon M, et al.
Publicado: (2015)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

2198. Healthcare Utilization During Acute Medically Attended Respiratory Syncytial Virus (RSV) Episodes among Infants in the United States
por: Gantenberg, Jason, et al.
Publicado: (2022)

Characterizing Mucociliary Clearance in Young Children with Cystic Fibrosis
por: Laube, Beth L., et al.
Publicado: (2022)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

CyFi-MAP: an interactive pathway-based resource for cystic fibrosis
por: Pereira, Catarina, et al.
Publicado: (2021)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.
por: Blanchette, Christopher M., et al.
Publicado: (2017)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Normalized T1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients - A Cross-Sectional Study
por: Dasenbrook, Elliott C., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r331v46mh80en9om4c5d3g3pmq